David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 35,730 shares at $289.48 ($10.3M) on 2022-07-19, disclosed to the SEC on 2022-07-21.
Open-market sale of $10.3M VRTX by EVP, Global Research and CSO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $286.72 | 963 | $276K | 2.7% |
| 2 | $286.72 | 963 | $276K | 2.7% |
| 3 | $287.83 | 4,561 | $1.3M | 12.7% |
| 4 | $287.83 | 4,561 | $1.3M | 12.7% |
| 5 | $288.67 | 5,737 | $1.7M | 16.1% |
| 6 | $288.67 | 5,737 |
| $1.7M |
| 16.1% |
| 7 | $289.48 | 6,604 | $1.9M | 18.5% |
| 8 | $289.48 | 6,604 | $1.9M | 18.5% |
| Total | $288.65 avg | 35,730 | $10.3M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |